+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Therapy Drugs for Melanoma Market - Global Forecast 2026-2032- Product Image
Targeted Therapy Drugs for Melanoma Market - Global Forecast 2026-2032- Product Image
Sale

Targeted Therapy Drugs for Melanoma Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6079690
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted Therapy Drugs for Melanoma Market is projected to reach USD 8.06 Billion in 2026. It is expected to continue growing at a CAGR of 9.32%, reaching USD 13.86 Billion by 2032.

Targeted Therapy Drugs for Melanoma: Executive Overview

Targeted therapy drugs for melanoma are medicines designed to inhibit molecular abnormalities that support tumor growth and survival. Their clinical use is concentrated in biomarker-defined disease, particularly tumors involving the BRAF-MEK signaling pathway, and is guided by diagnostic testing, disease stage, prior treatment, tolerability, and patient preferences. The treatment landscape is increasingly integrated with immunotherapy, surgery, radiotherapy, and molecular monitoring rather than viewed as a standalone intervention.

Precision Oncology Is Reshaping Melanoma Treatment

Melanoma care has shifted from largely histology-based decision-making toward molecularly informed treatment selection. Routine or expanding use of genomic testing helps identify actionable alterations, while combination regimens, treatment sequencing, and management of acquired resistance remain central clinical issues. Additional changes include stronger attention to adjuvant treatment, management of advanced disease, real-world tolerability, and equitable access to specialist oncology services and validated diagnostics.

Artificial Intelligence Strengthens Biomarker and Treatment Decisions

Artificial intelligence can support melanoma drug development and care by improving image interpretation, genomic pattern recognition, clinical-trial matching, adverse-event surveillance, and analysis of treatment response. Its practical value depends on representative training data, external validation, transparent performance assessment, and integration with pathology and oncology workflows. AI should assist-not replace-clinicians, particularly when treatment choices involve competing risks, limited evidence, or complex resistance patterns.

Regional Differences Reflect Access, Diagnostics, and Care Infrastructure

North America generally benefits from extensive oncology infrastructure, molecular diagnostics, and clinical-trial activity, although affordability and coverage variation remain important considerations. Europe combines established regulatory and guideline frameworks with differences in reimbursement and national health-system access. Asia-Pacific includes advanced melanoma centers alongside rapidly developing treatment and diagnostic capacity. Latin America faces uneven access to specialist care, testing, and innovative medicines. The Middle East shows concentrated investment in tertiary healthcare but substantial variation among health systems, while Africa continues to face gaps in oncology infrastructure, pathology capacity, and timely diagnosis.

International Groupings Reveal Uneven Policy and Procurement Priorities

Within ASEAN, differences in healthcare financing, diagnostic availability, and specialist capacity shape access to targeted melanoma treatment. BRICS members combine large patient populations and expanding oncology capabilities with significant variation in reimbursement and domestic manufacturing capacity. The European Union benefits from coordinated scientific and regulatory initiatives, but national decisions still influence availability. G7 countries generally possess mature precision-oncology ecosystems, while NATO members span highly diverse health systems and procurement environments. GCC states often have comparatively strong tertiary-care investment, with access shaped by referral pathways, localization, and public-private healthcare arrangements.

Country Perspectives on Diagnostics, Access, and Clinical Integration

Australia and New Zealand-linked clinical practice environments emphasize specialist melanoma management and molecular testing. The United States and Canada have broad access to precision-oncology services, with coverage and regional availability still affecting treatment pathways. France, Germany, Italy, Spain, and the United Kingdom operate within established European oncology systems, but reimbursement, assessment, and referral processes differ. Japan and South Korea combine advanced cancer centers with distinct regulatory and clinical practice frameworks. China and India are expanding oncology and diagnostic capacity while confronting geographic and affordability disparities. Brazil and Mexico are strengthening specialized cancer services but continue to experience uneven access between major urban centers and other areas. Russia’s treatment environment is influenced by healthcare-system capacity, procurement conditions, and availability of specialized diagnostics.

Prioritize Biomarker Access, Resistance Management, and Patient-Centered Delivery

Industry leaders should invest in reliable companion-diagnostic pathways, evidence generation across diverse populations, and clinical programs that address acquired resistance and treatment sequencing. Partnerships with laboratories and health systems can improve testing turnaround and referral coordination. Patient-support initiatives should focus on adherence, toxicity education, travel barriers, and financial navigation without substituting for sustainable coverage. Organizations should also strengthen post-market safety monitoring, use AI only under robust governance, and align evidence packages with the distinct regulatory and reimbursement requirements of each geography.

Methodology: Evidence-Based Review of the Targeted Melanoma Therapy Landscape

This executive summary is based on a structured synthesis of established clinical, regulatory, and healthcare-system evidence concerning targeted medicines for melanoma. The review considers treatment biology, biomarker testing, clinical integration, resistance, access conditions, regional and country-level infrastructure, and responsible use of artificial intelligence. Findings are framed qualitatively and exclude market estimates, market sizing, market shares, forecasts, and company-specific assessments. Because access and recommendations can change, clinical decisions should rely on current local guidelines, regulatory information, and multidisciplinary specialist review.

Targeted Therapy’s Value Depends on Precision and Health-System Readiness

Targeted therapy drugs have become an important component of biomarker-driven melanoma care, especially when molecular testing identifies an actionable pathway and treatment can be integrated into a broader management plan. Future progress will depend less on drug selection alone than on timely diagnosis, dependable testing, resistance-aware sequencing, equitable reimbursement, and coordinated specialist care. Regional and country differences make locally adapted implementation essential, while carefully governed AI can improve efficiency and evidence generation without weakening clinical accountability.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Targeted Therapy Drugs for Melanoma Market, by Mechanism Of Action
7.1. Introduction
7.2. BRAF Inhibitors
7.2.1. Dabrafenib
7.2.2. Encorafenib
7.2.3. Vemurafenib
7.3. CTLA-4 Inhibitors
7.4. MEK Inhibitors
7.4.1. Binimetinib
7.4.2. Cobimetinib
7.4.3. Trametinib
7.5. PD-1 Inhibitors
7.5.1. Nivolumab
7.5.2. Pembrolizumab
8. Targeted Therapy Drugs for Melanoma Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Targeted Therapy Drugs for Melanoma Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Targeted Therapy Drugs for Melanoma Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Targeted Therapy Drugs for Melanoma Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Center
11.3. Hospital
11.4. Oncology Center
12. Targeted Therapy Drugs for Melanoma Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Targeted Therapy Drugs for Melanoma Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Targeted Therapy Drugs for Melanoma Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Amgen Inc.
16.2. AstraZeneca PLC
16.3. Bayer AG
16.4. Bristol Myers Squibb Company
16.5. Eli Lilly and Company
16.6. GlaxoSmithKline plc
16.7. Johnson & Johnson Services, Inc.
16.8. Merck & Co., Inc.
16.9. Novartis AG
16.10. Pfizer Inc.
16.11. Regeneron Pharmaceuticals, Inc.
16.12. Roche Holding AG
16.13. Sanofi S.A.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Targeted Therapy Drugs for Melanoma Market, Years Considered for the Study
FIGURE 2. Global Targeted Therapy Drugs for Melanoma Market, Research Design
FIGURE 3. Global Targeted Therapy Drugs for Melanoma Market, Research Framework
FIGURE 4. Global Targeted Therapy Drugs for Melanoma Market, Data Triangulation
FIGURE 5. Global Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 7. Global Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2025 vs 2032 (%)
FIGURE 11. Global Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Targeted Therapy Drugs for Melanoma Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Targeted Therapy Drugs for Melanoma Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Targeted Therapy Drugs for Melanoma Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Targeted Therapy Drugs for Melanoma Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Targeted Therapy Drugs for Melanoma Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Targeted Therapy Drugs for Melanoma Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Targeted Therapy Drugs for Melanoma Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Targeted Therapy Drugs for Melanoma Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Targeted Therapy Drugs for Melanoma Market Segmentation & Coverage
TABLE 2. Global Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 3. Global Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 4. Global BRAF Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global BRAF Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global BRAF Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Dabrafenib Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Dabrafenib Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Dabrafenib Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Encorafenib Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Encorafenib Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Encorafenib Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Vemurafenib Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Vemurafenib Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Vemurafenib Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global CTLA-4 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global CTLA-4 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global CTLA-4 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global MEK Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global MEK Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global MEK Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Binimetinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Binimetinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Binimetinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Cobimetinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Cobimetinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Cobimetinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Trametinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Trametinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Trametinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global PD-1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global PD-1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global PD-1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Nivolumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Nivolumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Nivolumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Pembrolizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Pembrolizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Pembrolizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 41. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 48. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 58. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 68. Global Ambulatory Surgical Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Ambulatory Surgical Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Ambulatory Surgical Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Oncology Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Oncology Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Oncology Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Targeted Therapy Drugs for Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. North America Targeted Therapy Drugs for Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. North America Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 89. North America Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 90. North America Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 91. North America Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 92. North America Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 93. North America Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 94. North America Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. North America Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. Latin America Targeted Therapy Drugs for Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Latin America Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 98. Latin America Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 99. Latin America Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 100. Latin America Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 101. Latin America Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 102. Latin America Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 103. Latin America Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Latin America Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Europe Targeted Therapy Drugs for Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Europe Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 107. Europe Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 108. Europe Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 109. Europe Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 110. Europe Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 111. Europe Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 112. Europe Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Europe Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Middle East Targeted Therapy Drugs for Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Middle East Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 116. Middle East Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 117. Middle East Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 118. Middle East Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 119. Middle East Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 120. Middle East Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 121. Middle East Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. Middle East Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. Africa Targeted Therapy Drugs for Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Africa Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 125. Africa Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 126. Africa Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 127. Africa Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 128. Africa Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 129. Africa Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 130. Africa Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. Africa Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. Global Targeted Therapy Drugs for Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 135. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 136. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 137. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 138. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 139. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 140. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. ASEAN Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. GCC Targeted Therapy Drugs for Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. GCC Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 144. GCC Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 145. GCC Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 146. GCC Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 147. GCC Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 148. GCC Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 149. GCC Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. GCC Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. European Union Targeted Therapy Drugs for Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. European Union Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 153. European Union Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 154. European Union Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 155. European Union Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 156. European Union Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 157. European Union Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 158. European Union Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. European Union Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. BRICS Targeted Therapy Drugs for Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. BRICS Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 162. BRICS Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 163. BRICS Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 164. BRICS Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 165. BRICS Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 166. BRICS Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 167. BRICS Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. BRICS Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. G7 Targeted Therapy Drugs for Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. G7 Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 171. G7 Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 172. G7 Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 173. G7 Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 174. G7 Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. G7 Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 176. G7 Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. G7 Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. NATO Targeted Therapy Drugs for Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. NATO Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 180. NATO Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 181. NATO Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 182. NATO Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 183. NATO Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 184. NATO Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 185. NATO Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. NATO Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Global Targeted Therapy Drugs for Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 188. United States Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 189. United States Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 190. United States Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 191. United States Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 192. United States Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 193. United States Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 194. United States Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 195. United States Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. United States Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. Canada Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 198. Canada Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 199. Canada Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 200. Canada Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 201. Canada Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 202. Canada Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 203. Canada Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 204. Canada Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Canada Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. Mexico Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 207. Mexico Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 208. Mexico Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 209. Mexico Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 210. Mexico Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 211. Mexico Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 212. Mexico Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 213. Mexico Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. Mexico Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Brazil Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 216. Brazil Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 217. Brazil Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 218. Brazil Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 219. Brazil Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 220. Brazil Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 221. Brazil Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 222. Brazil Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Brazil Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 225. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 226. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 227. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 228. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 229. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 230. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 231. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. United Kingdom Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. Germany Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 234. Germany Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 235. Germany Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 236. Germany Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 237. Germany Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 238. Germany Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 239. Germany Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 240. Germany Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. Germany Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. France Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 243. France Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 244. France Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 245. France Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 246. France Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 247. France Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 248. France Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 249. France Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. France Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. Russia Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 252. Russia Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 253. Russia Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 254. Russia Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 255. Russia Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 256. Russia Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 257. Russia Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 258. Russia Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. Russia Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. Italy Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 261. Italy Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 262. Italy Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 263. Italy Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 264. Italy Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 265. Italy Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 266. Italy Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 267. Italy Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. Italy Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. Spain Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 270. Spain Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 271. Spain Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 272. Spain Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 273. Spain Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 274. Spain Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 275. Spain Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 276. Spain Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Spain Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 278. China Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 279. China Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 280. China Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 281. China Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 282. China Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 283. China Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 284. China Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 285. China Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. China Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 287. India Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 288. India Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 289. India Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 290. India Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 291. India Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 292. India Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 293. India Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 294. India Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. India Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. Japan Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 297. Japan Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 298. Japan Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 299. Japan Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 300. Japan Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 301. Japan Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 302. Japan Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 303. Japan Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 304. Japan Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 305. Australia Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 306. Australia Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 307. Australia Targeted Therapy Drugs for Melanoma Market Size, by BRAF Inhibitors, 2017-2032 (USD Million)
TABLE 308. Australia Targeted Therapy Drugs for Melanoma Market Size, by MEK Inhibitors, 2017-2032 (USD Million)
TABLE 309. Australia Targeted Therapy Drugs for Melanoma Market Size, by PD-1 Inhibitors, 2017-2032 (USD Million)
TABLE 310. Australia Targeted Therapy Drugs for Melanoma Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 311. Australia Targeted Therapy Drugs for Melanoma Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 312. Australia Targeted Therapy Drugs for Melanoma Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. Australia Targeted Therapy Drugs for Melanoma Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. South Korea Targeted Therapy Drugs for Melanoma Market Size, 2017-2032 (USD Million)
TABLE 315. South Korea Targeted Therapy Drugs for Melanoma Market Size, by Mechanism Of Action,

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.

Related Topics

Related Reports

Combination Therapies for Melanoma Market - Global Forecast 2026-2032 - Product Image

Combination Therapies for Melanoma Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Ocular Melanoma Market: Focus on Type, Treatment, Country and Regional Analysis, 2025-2035 - Product Image

Ocular Melanoma Market: Focus on Type, Treatment, Country and Regional Analysis, 2025-2035

  • Report
  • Global
From
Melanoma Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035 - Product Image

Melanoma Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035

  • Report
  • Global
From
Melanoma Drug Market - Global Forecast 2026-2032 - Product Image

Melanoma Drug Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Tumor-Infiltrating Lymphocyte (TIL) Therapies - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036 - Product Image

Tumor-Infiltrating Lymphocyte (TIL) Therapies - Market Size, Target Population, Competitive Landscape & Market Forecast - 2036

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.